In patients with albuminuric chronic kidney disease and type 2 diabetes, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, exhibited significant cardiovascular benefits, particularly in reducing heart failure (HF) risks. Analyses from the FIGARO-DKD trials revealed that finerenone lowered the incidence of new-onset HF, cardiovascular death, and hospitalizations for HF compared to placebo. These benefits extended across various HF outcomes, including a reduction in total HF hospitalizations by 30%, demonstrating finerenone’s efficacy in mitigating HF-related morbidity and mortality in this high-risk patient population, regardless of prior HF history.

The findings underscore finerenone’s potential as a therapeutic option for HF prevention in patients with chronic kidney disease and type 2 diabetes. The observed benefits of finerenone were consistent across subgroups, suggesting its efficacy remains irrespective of patients’ baseline HF status. These results emphasize the significance of finerenone in improving cardiovascular outcomes in this vulnerable population and highlight the need for further exploration of its long-term impact on HF prevention and management.

Reference: Filippatos G, Anker SD, Agarwal R, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13. PMID: 34775784; PMCID: PMC8812430.